Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lucia Moiola

Showing results (11-20 of 154) with videos related to

Pageof 16
Sort By:
Journal of Neurology|April 14, 2021
Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?Mario Orrico, Agostino Nozzolillo, Stefano Gelibter, et al.
Multiple Sclerosis and Related Disorders|December 17, 2018
Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuationVittorio Martinelli, Gloria Dalla Costa, Francesca Sangalli, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 23, 2021
Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year StudyPaolo Preziosa, Loredana Storelli, Alessandro Meani, et al.
Plos One|December 21, 2016
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryLuca Prosperini, Nicola de Rossi, Cristina Scarpazza, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 1, 2020
Two-year regional grey and white matter volume changes with natalizumab and fingolimodPaolo Preziosa, Maria A Rocca, Elisabetta Pagani, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMSAngelo Ghezzi, Giancarlo Comi, Luigi Maria Grimaldi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 2, 2022
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease ProgressionPaolo Preziosa, Elisabetta Pagani, Alessandro Meani, et al.
Journal of Neurology|April 7, 2023
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational studyChiara Zanetta, Maria A Rocca, Alessandro Meani, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 13, 2016
Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two casesPaolo Preziosa, Francesca Sangalli, Federica Esposito, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 11, 2019
Changes in cortical motor outputs after a motor relapse of multiple sclerosisRaffaella Chieffo, Laura Straffi, Alberto Inuggi, et al.
Pageof 16

Showing results (11-20 of 154) with videos related to

Sort By:
Pageof 16
Journal of Neurology|April 14, 2021
Atrioventricular block after fingolimod resumption: a consequence of sphingosine-1-phosphate axis alteration due to COVID-19?Mario Orrico, Agostino Nozzolillo, Stefano Gelibter, et al.
Multiple Sclerosis and Related Disorders|December 17, 2018
Severe disease activity in a patient with multiple sclerosis after daclizumab discontinuationVittorio Martinelli, Gloria Dalla Costa, Francesca Sangalli, et al.
Neurotherapeutics : the Journal of the American Society for Experimental Neurotherapeutics|January 23, 2021
Effects of Fingolimod and Natalizumab on Brain T1-/T2-Weighted and Magnetization Transfer Ratios: a 2-Year StudyPaolo Preziosa, Loredana Storelli, Alessandro Meani, et al.
Plos One|December 21, 2016
Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent RegistryLuca Prosperini, Nicola de Rossi, Cristina Scarpazza, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 1, 2020
Two-year regional grey and white matter volume changes with natalizumab and fingolimodPaolo Preziosa, Maria A Rocca, Elisabetta Pagani, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|July 30, 2019
Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMSAngelo Ghezzi, Giancarlo Comi, Luigi Maria Grimaldi, et al.
Neurology(R) Neuroimmunology & Neuroinflammation|February 2, 2022
Slowly Expanding Lesions Predict 9-Year Multiple Sclerosis Disease ProgressionPaolo Preziosa, Elisabetta Pagani, Alessandro Meani, et al.
Journal of Neurology|April 7, 2023
Effectiveness and safety profile of cladribine in an Italian real-life cohort of relapsing-remitting multiple sclerosis patients: a monocentric longitudinal observational studyChiara Zanetta, Maria A Rocca, Alessandro Meani, et al.
Neurological Sciences : Official Journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology|November 13, 2016
Clinical deterioration due to co-occurrence of multiple sclerosis and glioblastoma: report of two casesPaolo Preziosa, Francesca Sangalli, Federica Esposito, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|October 11, 2019
Changes in cortical motor outputs after a motor relapse of multiple sclerosisRaffaella Chieffo, Laura Straffi, Alberto Inuggi, et al.
Pageof 16